Print

Lay Description

To investigate the efficacy, safety and tolerability of BI 409306 once daily compared to placebo given for 52 weeks to subjects with attenuated psychosis syndrome.

Category

  • Aging and Geriatric
  • Genetics
IRB Number
20180639HU
NCT Number
ct.gov registration not required
Open to Enrollment
Yes

Eligibility

Eligible Ages
Between 16 Years and 30 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups

Study Contact


Regulatory Point of Contact
David Glahn
david.glahn@childrens.harvard.edu

Regulatory Point of Contact
Floyd Jones
(210) 567-5625
jonesfa@uthscsa.edu

Regulatory Point of Contact
Amy Saklad
(210) 567-8229
saklada@uthscsa.edu

Regulatory Point of Contact
Mary Woolsey
(210)567-8049
woolseym@uthscsa.edu

Local Recruitment Point of Contact
Floyd Jones
(210) 567-5625
jonesfa@uthscsa.edu

Local Recruitment Point of Contact
Amy Saklad
(210) 567-8229
saklada@uthscsa.edu

Local Recruitment Point of Contact
Mary Woolsey
(210)567-8049
woolseym@uthscsa.edu

Principal Investigator
David Glahn